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CSF tau is associated with impaired 
cortical plasticity, cognitive 
decline and astrocyte survival only 
in APOE4-positive Alzheimer’s 
disease
Giacomo Koch  1,2, Francesco Di Lorenzo1,3, Stefano Loizzo4, Caterina Motta1,3, Sara 
Travaglione4, Monica Baiula5, Roberto Rimondini6, Viviana Ponzo1, Sonia Bonnì1, Sofia 
Toniolo3, Fabrizio Sallustio2, Marco Bozzali7, Carlo Caltagirone1,2, Gabriele Campana5 & 
Alessandro Martorana1,3
In Alzheimer’s disease (AD) patients, apopoliprotein (APOE) polymorphism is the main genetic factor 
associated with more aggressive clinical course. However, the interaction between cerebrospinal 
fluid (CSF) tau protein levels and APOE genotype has been scarcely investigated. A possible key 
mechanism invokes the dysfunction of synaptic plasticity. We investigated how CSF tau interacts 
with APOE genotype in AD patients. We firstly explored whether CSF tau levels and APOE genotype 
influence disease progression and long-term potentiation (LTP)-like cortical plasticity as measured by 
transcranial magnetic stimulation (TMS) in AD patients. Then, we incubated normal human astrocytes 
(NHAs) with CSF collected from sub-groups of AD patients to determine whether APOE genotype and 
CSF biomarkers influence astrocytes survival. LTP-like cortical plasticity differed between AD patients 
with apolipoprotein E4 (APOE4) and apolipoprotein E3 (APOE3) genotype. Higher CSF tau levels were 
associated with more impaired LTP-like cortical plasticity and faster disease progression in AD patients 
with APOE4 but not APOE3 genotype. Apoptotic activity was higher when cells were incubated with 
CSF from AD patients with APOE4 and high tau levels. CSF tau is detrimental on cortical plasticity, 
disease progression and astrocyte survival only when associated with APOE4 genotype. This is relevant 
for new therapeutic approaches targeting tau.
Alzheimer’s disease (AD) is pathologically characterized by senile plaques, composed of extracellular aggregates 
of amyloid-β (Aβ) protein, and neurofibrillary tangles formed by hyperphosphorylated tau protein1. The accu-
mulation of Aβ begins before the onset of cognitive symptoms and it is followed by the spreading of tau pathology 
that has been related to the progression of cognitive decline2–5. The course of AD is also influenced by genetic 
factors such as the APOE genotype6. Having one or two copies of APOE E4 allele is associated with increased risk 
of developing AD7 and with a more aggressive disease course8. Although there is some evidence that APOE4 gen-
otype may be associated with more pronounced tau pathology9,10, it is still poorly understood how in AD patients 
APOE genotype may interact with underlying tau pathology.
A possible trait d’union could be the dysfunction of cortical plasticity, which is strictly linked to AD pathol-
ogy11. This is especially relevant since long-term potentiation (LTP) is considered a main neurophysiological 
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correlate of learning and memory12. Notably, APOE regulates these mechanisms in an isoform dependent man-
ner13 and tau pathology has a detrimental effect on synaptic plasticity14. Emerging evidence is promoting a novel 
framework in which astrocytes are powerful regulators of formation and refinement of synaptic plasticity15. 
Astrocytes are essential for the Aβ-induced tau phosphorylation in neurons16 and conversely tau protein plays a 
central role in inducing astrocytes apoptosis17. Astrocytes functions could critically influence brain plasticity and 
consequently neuronal survival in AD18.
Accordingly, we recently identified the disruption of LTP-like cortical plasticity as a core feature of AD by 
using transcranial magnetic stimulation (TMS)21. Indeed, an altered LTP-like cortical plasticity is associated with 
a more-severe cognitive decline19 and with higher CSF tau levels20. However, it is still unknown if CSF tau levels 
interacts with cortical plasticity and with disease severity depending on the APOE genotype. Therefore, in a first 
series of in vivo experiments performed in AD patients, we explored the influence of CSF tau levels on LTP-like 
cortical plasticity and on clinical progression, according to the APOE genotype. We hypothesized that if APOE4 
genotype is associated with more pronounced CSF tau pathology9,10, then we would expect in these patients an 
LTP-like cortical plasticity impairment and a more aggressive disease course, whose might be dependent on the 
CSF tau levels.
We also aimed at investigating the effects of CSF tau on synaptic impairment by exploring the influence of 
CSF tau on astrocytes survival22,23. Recent works showed that APOE isoforms influence the progression of AD by 
impairing astrocytes structure and function24 and tau protein is thought to play a central role in inducing astro-
cytes apoptosis25. Therefore, in a second series of in vitro experiments we incubated normal human astrocytes 
(NHAs)26 with CSF sampled from the same AD enrolled for the TMS experiments in order to verify the effects of 
CSF tau on astrocytes survival. We hypothesized that higher CSF tau levels would be more detrimental on astro-
cyte survival especially when associated with APOE4 genotype.
Results
Forty-one consecutive patients were recruited at the memory clinic of the University Hospital Tor Vergata, admit-
ted for complaining memory symptoms (Fig. 1). APOE4 and APOE3 groups did not differ in gender, education, 
age at disease onset, disease duration, or Mini-Mental State Examination (MMSE) score at baseline as shown in 
Table 1. The analysis of CSF protein contents showed increased, although not significant, total tau (t-tau) levels in 
the APOE4 (n = 20) as compared to the APOE3 (n = 21) group (t-tau: 723.4 ± 369.9 vs 547.2 ± 273.1, p = 0.08). 
There were no significant differences of Aβ1-42 and p-tau levels between the two groups (Aβ1-42: 317.6 ± 107.0 
vs 353.3 ± 145.3, p = 0.38; p-tau: 89.7 ± 47.3 vs 80.7 ± 46.0, p = 0.54).
During follow up AD patients in both APOE groups were all treated with standard acetylcholinesterase inhibi-
tor (AchEI) therapy (rivastigmine/donepezil). The two groups did not differ in the number of patients undergoing 
different AchEI treatment (APOE4: 12 patients under rivastigmine and 8 patients under donepezil treatment; 
APOE3: 13 patients under rivastigmine and 8 patients under donepezil treatment; p = 0.75). Follow-up evalua-
tion, with MMSE scores performed at 6, 12 and 18 months, revealed that APOE4 progress faster than APOE3 AD 
patients as shown by ANOVA (significant GROUP x TIME interaction (F(3, 117) = 3.2782, p = 0.024) (Fig. 2A). 
Post hoc analyses revealed that in APOE4 AD patients MMSE scores were lower than baseline evaluation as early 
as at 12 months (p = 0.00003) and showed a further step of decline between the 12 months and the 18 months 
follow-up (p < 0.00001). On the other hand, in APOE3 AD patients MMSE scores became significantly lower 
respect to baseline only after 18 months (p = 0.001).
Figure 1. The figure depicts the experimental setting. (A) After CSF collection and APOE genotype assessment, 
all patients underwent TMS applied over the primary motor cortex. MEPs were recorded before and after the 
iTBS protocol to evaluate cortical plasticity. (B) NHAs were incubated in CSF derived from AD patients, divided 
in groups according to APOE genotype and CSF t-tau levels, and HC. Cell viability and caspase 3/7 levels were 
evaluated after 24 hours, 5 days and 7 days of incubation.
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Cortical plasticity. The TMS procedures were well tolerated in all subjects. The mean resting motor thresh-
old (RMT) to TMS did not different between APOE3 and APOE4 AD groups, but was lower in both APOE3 
(p = 0.007) and APOE4 (p = 0.001) AD patients compared to healthy subjects (HS) (APOE4: 35.7% ± 1.43 maxi-
mum stimulator output; APOE3: 38.6% ± 1.94 maximum stimulator output; HS: 43.7% ± 1.49 maximum stimu-
lator output). Baseline mean motor evoked potentials (MEPs) amplitude did not differ between APOE4, APOE3 
AD patients and HS (APOE4: 1.11 ± 0.64 mV; APOE3: 1.06 ± 0.45 mV; HS: 1.09 ± 0.58 mV). ANOVA analysis 
performed on the intermittent-theta burst stimulation (iTBS) protocol showed a significant GROUP main fac-
tor (F(1,39) = 6.08; p = 0.01) and GROUP x TIME interaction (F(8, 236) = 2.498; p = 0.013), but not for TIME 
(F(4, 156) = 1.99; p = 0.09) main factor. Post hoc analyses with Bonferroni correction showed that AD patients 
with APOE3 and APOE4 genotype had less LTP in comparison to healthy controls at 10, 15, 20 and 25 min-
utes (p < 0.0001 for both comparisons) and that AD patients with APOE3 genotype showed a more pronounced 
tendency towards long term depression (LTD) in comparison to AD patients with APOE4 genotype at 10 and 
25 minutes (both p < 0.05) (Fig. 2B).
Interaction between CSF tau levels, cortical plasticity and cognitive decline according to APOE 
genotype. We performed separate correlation analyses in order to investigate the relationship between cor-
tical plasticity and CSF biomarkers according to APOE genotype. We found that higher CSF t-tau levels were 
associated with more impaired cortical plasticity (as indexed by the individual amount of mean change in MEPs’ 
amplitude after the iTBS protocol) in the APOE4 but not in the APOE3 group (APOE4: p = 0.005, r = −0.61; 
APOE3: p = 0.55, r = −0.13) (Fig. 3A). Similar results were found for CSF p-tau (APOE4: p = 0.01, r = −0.54; 
APOE3: p = 0.19, r = −0.29) (Fig. 3B), but not for CSF Aβ1-42 levels (APOE4: p = 0.99, r = 0.01; APOE3: p = 0.88, 
r = −0.03) (Fig. 3C).
APOE4 APOE3 HS p value
Subjects (n) 20 21 20
Sex (M:F) 10:10 11:10 10:10 n.s.
Age at baseline, y 
(mean ± SD) 70.3 ± 2.4 71.8 ± 2.1 70.1 ± 3.4 n.s.
Formal education, y 
(mean ± SD) 8.5 ± 4.0 8.1 ± 4.2 8.7 ± 4.4 n.s.
Disease duration, y 
(mean ± SD) 1.6 ± 0.6 2.1 ± 0.7 n.s.
MMSE at baseline 
(mean ± SD) 21.7 ± 4.3 23.0 ± 3.4 n.s.
CSF t-tau (pg/ml) 723.4 ± 369.9 547.2 ± 273.1 0.08
CSF p-tau (pg/ml) 89.7 ± 47.3 80.7 ± 46.0 0.54
CSF Aβ1-42 (pg/ml) 317.6 ± 107.0 353.3 ± 145.3 0.38
Table 1. Demographic characterization of Alzheimer’s disease patients and healthy subjects recruited for 
transcranial magnetic stimulation experiments. M: male; F: female; y: years; SD: standard deviation; MMSE: 
Mini Mental State Examination; n.s.: not significant.
Figure 2. (A) Two-way repeated-measures ANOVA performed on MMSE assessed at baseline and at 6, 12 
and 18 months in the two groups of AD patients. Error bars indicate standard deviation. *Indicate p < 0.05 in 
comparison with baseline. (B) Two-way repeated-measures ANOVA performed on the iTBS protocol after-
effects on MEPs’ amplitude in HS and in the different groups of AD patients according to APOE genotype. Error 
bars indicate standard error of mean. *Indicate p < 0.05 for the comparison between HS and both APOE3 and 
APOE4 AD groups. °Indicate p < 0.05 for the comparison between APOE3 and APOE4 group.
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We then explored the correlation between CSF biomarkers and cognitive decline. Higher CSF t-tau levels cor-
related with faster cognitive decline (as indexed by delta MMSE score) only in the APOE4 but not in the APOE3 
group (APOE4: p = 0.04, r = −0.45; APOE3: p = 0.33, r = −0.22) (Fig. 4A). On the other hand, CSF levels of p-tau 
(APOE4: p = 0.45, r = −0.18; APOE3: p = 0.65, r = −0.10) (Fig. 4B) and Aβ1-42 did not correlate with cognitive 
decline in both APOE groups (APOE4: p = 0.78, r = 0.07; APOE3: p = 0.35, r = −0.21) (Fig. 4C).
We also found that AD presenting with more altered cortical plasticity showed a more pronounced cogni-
tive decline at 18 months, in agreement with our previous findings19. In fact, the mean individual response to 
the iTBS correlated with delta MMSE scores at 18 months in both APOE3 and APOE4 AD patients (APOE3: 
p = 0.003, r = 0.61; APOE4: p = 0.021, r = 0.51). However, CSF t-tau levels had a strong influence on the rela-
tionship between cortical plasticity and cognitive decline depending on the APOE genotype. In this analysis, AD 
patients were stratified according to CSF t-tau levels into high CSF t-tau levels and low CSF t-tau levels, using as 
cut-off value the median of CSF tau levels of our entire sample (680 pg/ml). We found that APOE4 patients with 
high CSF t-tau levels showed a response to the iTBS protocol towards LTD, while conversely, APOE4 patients 
with low CSF t-tau showed a tendency to form LTP (Fig. 5A). On the other hand, in the APOE3 group, we did 
Figure 3. Pearson’s r correlation matrices between the individual amount of mean change in MEPs’ amplitude 
induced by iTBS protocol and CSF values of t-tau (A), p-tau (B) and Aβ1-42 (C) according to APOE genotype.
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not observe any specific distribution according to CSF t-tau levels (Fig. 5B), since all patients showed a uniform 
response to the iTBS protocol towards LTD.
Normal human astrocytes cultures. A second series of combined in vitro experiments was performed 
on cell cultures using human CSF as incubation medium as previously reported27. NHAs cultures were incubated 
with CSF collected from AD patients recruited from those enrolled for the assessment of cortical plasticity. CSF 
samples from 16 AD patients grouped according to CSF t-tau levels, using as cut-off value the median of CSF tau 
levels of all our sample (680 pg/ml), and APOE genotype, resulting in 4 groups (each one consisting of four sub-
jects), namely APOE3 low t-tau levels (LTE3), APOE3 high t-tau levels (HTE3), APOE4 low t-tau levels (LTE4) 
and APOE4 high t-tau levels (HTE4). The four resulting groups were matched for sex, age, MMSE at the baseline 
and disease onset (Table 2).
Figure 4. Pearson’s r correlation matrices between cognitive progression, expressed as difference between 
MMSE score at 18 months follow-up and baseline, and CSF values of t-tau (A), p-tau (B) and Aβ1-42 (C) 
according to APOE genotype.
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Astrocytes viability. To assess the effect of CSF incubation on physiological status of astrocytes, we ana-
lyzed cell viability using 7-amino actinomycin D (7-AAD), a membrane impermeant dye that is generally 
excluded from viable cells. A general time-dependant decrease in NHAs viability was detected during long-term 
CSF incubation. We found no differences among all CSF treated samples at 24 hours and 5 days (Fig. 6A); con-
versely, at 7 days HTE4 sample showed significantly lower viability when compared to LTE4 and control samples 
(Kruskal-Wallis test: p = 0.0002; Dunn’s multiple comparisons post hoc test: HTE4 vsHCp = 0.03; HTE4 vs LTE4 
p = 0.04). Hence, the results of this experiment show that the coexistence of high CSF levels of t-tau and APOE4 
genotype is able to influence astrocytes viability; conversely CSF t-tau levels do not induce any change when 
associated to APOE3 genotype.
Levels of apoptosis in NHA. Cell viability loss is often linked to apoptosis and the activation of caspases, 
a milestone in the path of programmed cell death, leads to proteolytic cleavage of several neuronal proteins in 
AD28. Several studies suggest that activation of caspases and cleavage of cellular proteins may contribute to astro-
cyte injury and damage in the AD patient brain29. Thus, to evaluate the effect of CSF incubation on apoptosis 
in NHAs, we employed two approaches to detect early apoptosis by measuring the activity of caspase 3/7 and 
annexin V/7AAD after 24 hours, 5 days and 7 days of incubation. We found that activated caspase 3/7 levels were 
similar among groups until day 7 (Fig. 6B), when we observed higher activated caspase level in the HTE4 respect 
to LTE4, APOE3 and control groups (ANOVA p < 0.0001; HTE4 vs all p < 0.01). Similar results were obtained 
from Annexin V assay (Fig. 6C). In fact, after 24 hours and 5 days of incubation we did not observe any variation 
in apoptotic levels while astrocytes treated with HTE4 for 7 days showed the highest percentage of early apoptotic 
cells, if compared to all other groups (ANOVA p < 0.0001; HTE4 vs all p < 0.01). No differences were observed 
between LTE3 and HTE3 (Fig. 6B and C), suggesting that t-tau levels might be the factor responsible for cell 
apoptosis only in NHAs treated with CSF from patients with APOE4 isoform.
Discussion
We provide novel evidence that the presence of APOE polymorphisms imply different mechanisms of CSF 
tau-related dysfunction in AD patients. Our work reveals that high CSF tau levels are associated with impaired 
Figure 5. Pearson’s r correlation matrices between the individual amount of mean change MEPs’ amplitude 
induced by iTBS and the cognitive progression, expressed as delta of MMSE scores at 18 months follow up, in 
APOE4 (A) and APOE3 (B) AD. White dots represent low (<680 pg/mL) CSF t-tau levels, black dots represent 
high (>680 pg/mL) CSF t-tau levels.
LTE3 LTE4 HTE3 HTE4 CTRL p value
Subjects (n) 4 4 4 4 4
Sex (M:F) 2:2 2:2 2:2 2:2 2:2 n.s.
Age at baseline, y 
(mean ± SD) 74.2 ± 2.2 74.3 ± 1.9 72.3 ± 1.9 71.4 ± 2.8 69.1 ± 3.8 n.s.
Disease duration, y 
(mean ± SD) 1.9 ± 0.5 1.8 ± 0.6 2.2 ± 0.6 1.7 ± 0.8 n.a. n.s.
MMSE at baseline 
(mean ± SD) 23.5 ± 2.8 23.1 ± 2.7 21.3 ± 2.9 21.4 ± 2.9 n.a. n.s.
CSF t-tau (pg/ml) 386.5 ± 51.6a 378.3 ± 49.6a 1008.0 ± 199.4 1010.2 ± 180.7 178.3 ± 115.5a <0.01
CSF p-tau (pg/ml) 49.5 ± 18.0a 61.4 ± 22.5a 128.6 ± 33.8 110.2 ± 30.7 28.3 ± 9.5a <0.01
CSF Aβ1-42 (pg/ml) 318.7 ± 34.1 280.4 ± 39.6 360.2 ± 40.2 314.9 ± 27.8 798.5 ± 88.7b <0.01
Table 2. Demographic and clinical characterization of Alzheimer’s disease patients and control subjects 
recruited for experiments on normal human astrocytes incubated with CSF. M: male; F: female; y: years; SD: 
standard deviation; MMSE: Mini Mental State Examination; n.s.: not significant. p value expressed for Kruskal-
Wallis/ aDifference vs HTE3 and HTE4. bDifference vs CTRL.
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cortical plasticity and disease progression only in AD patients carrying APOE4 but not APOE3 genotype. In 
parallel, we also found that CSF tau levels influence apoptosis in NHAs when incubated with CSF collected from 
AD patients with APOE4 but not APOE3 genotype. Taken together these findings reveal that CSF tau levels are 
linked to cortical plasticity, cognitive decline and astrocytes survival only when associated with APOE4 genotype.
In our study, APOE3 and APOE4 AD patients did not initially differ in terms of neuropsychological symp-
toms and degree of functional status, thus making them indistinguishable from a clinical point of view, at least at 
the time of their first visit to the memory clinic. Indeed, our follow up evaluations revealed that the two groups 
show divergent clinical progression, since APOE4 group worsen faster than APOE3, accordingly to previous 
evidence30–32.
Both APOE4 and APOE3 AD patients showed, as expected, an impairment of LTP-like cortical plasticity19,20. 
Interestingly, APOE3 patients showed an evident tendency to form paradoxical LTD instead of the expected 
LTP-like cortical plasticity in comparison to APOE4 patients. This different profile of LTP-like cortical plasticity 
dysfunction can be explained according to the extensive experimental works in animal models of AD reveal-
ing that APOE polymorphism has a profound influence on disease-related synaptic dysfunction15. These studies 
showed that APOE selectively impairs glutamatergic neurotransmission and LTP by reducing NMDA and AMPA 
receptor functions33. In particular it was found that LTP is more impaired in APOE2 and APOE3 in comparison 
to APOE4 mice34,35. This is compatible with our findings, showing a relative less impaired LTP in APOE4 in 
Figure 6. One-way ANOVA on NHAs viability (A) caspase 3/7 levels (B) and early apoptotic levels (C) at 
24 hours, 5 days and 7 days of incubation with CSF of AD patients, divided in groups according to APOE 
genotype and t-tau levels, and control subjects. Results are expressed as mean ± standard deviation of three 
independent experiments carried out in duplicate. *Indicate p < 0.05 for the post hoc multiple comparisons test.
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comparison with APOE3 AD patients. It is possible that such differences could involve complex interactions with 
glutamatergic transmission36, although the exact mechanisms remain to be clarified in further studies.
In our sample, faster cognitive decline was associated with more impaired LTP-like cortical plasticity, a con-
dition observed in both APOE3 and APOE4 group, confirming previous observations that an altered cortical 
plasticity could be involved in fastened clinical worsening19,20,22. However, we found a striking difference when 
considering the interaction between disease progression and CSF tau levels according to the APOE genotype. 
Only in APOE4 AD patients there is a strong association between cognitive decline, impaired cortical plasticity 
and CSF t-tau values, suggesting a relative susceptibility to APOE4 patients to the amount of tau-related patholog-
ical burden. On the other hand, this phenomenon is completely absent in APOE3 AD patients, which are indeed 
characterized by a strong correlation between LTP-like cortical plasticity dysfunction and cognitive decline, 
which is totally independent from CSF tau levels. Therefore, our data show a clear dependency on underlying 
CSF tau levels that is exclusive for APOE4 genotype. This finding is clinically relevant especially in light of recent 
findings showing that AD patients with very high levels of CSF tau and phosphorylated tau at threonine 181 
(p-tau181) exhibit worse clinical outcomes over time, including faster progression of cognitive deficits and a higher 
mortality5. In addition, they are also compatible with a recent work showing that CSF tau and p-tau181 levels, but 
not Aβ42 levels, predict subsequent rates of whole-brain and regional atrophy in AD over the next three years37. 
Other recent clinical evidence also supports this result: for instance, a recent longitudinal study of CSF biomark-
ers found that APOE4 genotype influences dramatically markers of neuronal injury inducing a constant increase 
of CSF t-tau and p-tau181 levels36, and higher CSF tau levels were specifically correlated with increased tau in the 
temporal lobe, a region involved in memory processing38. Indeed, there is an increased risk of progression from 
mild cognitive impairment to AD with elevated CSF t-tau and p-tau and with the presence of the APOE4 geno-
type, but not with decreased CSF Aβ42 levels39. Moreover, APOE4 may accelerate onset of dementia and neuronal 
degeneration by differentially impairing the maintenance of synaptic strength and reducing glutamate signaling 
proteins, even in the absence of overexpression of APP and Aβ APOE439.
The current neurophysiological and clinical findings were also paralleled by similar interactions between 
CSF tau levels and APOE genotype when examining astrocytes vulnerability. Notably, the CSF samples used as 
incubation medium for the astrocytes cultures were collected from the same AD patients in whom we assessed 
cortical plasticity. We found that NHAs were less viable and more susceptible to apoptosis when incubated with 
CSF obtained from APOE4 patients with high levels of CSF tau but not from APOE3 ones. We also found a 
similar phenomenon when evaluating the activation of caspases, a milestone in the path programmed of cell 
death known as apoptosis, occurring in AD and leads to proteolytic cleavage of several neuronal proteins40. In 
particular, the caspase-3 inhibits the production of ROS and is necessary for the efficient execution of apoptosis, 
while it is necessary for the effector caspase-7 cell detachment by apoptosis41. Several studies suggest that the 
plaques, tangles, and the activation of caspases share a common path and that induced caspase cleavage of tau 
plays an important role in the development of the disease neurofibrillary tangle42. Since caspase-3 activity can be 
also induced independently of apoptosis43 and apoptosis is not necessarily caspase-dependent44, we performed 
also the annexin V/7AAD assay in order to confirm the data on apoptosis deriving from caspase 3/7 activity. In 
fact, annexin V is a 35–36 kDa Ca2+-dependent phospholipid-binding protein with high affinity for membrane 
phosphatidylserine (PS) that binds to PS exposed on cell surface of apoptotic cells45.
This is relevant since a growing body of evidence shows that alterations in astrocytic functions have poten-
tially catastrophic consequences for neurons46,50. Moroever astrocytes apoptosis has been reported in several 
experimental25,47 and clinical neuropathological conditions including AD48,49 thereby reinforcing the notion that 
damage of astrocytes can contribute to disease progression.
Regarding the possible mechanisms underlying the current findings we can only speculate about possible sites 
of interaction between CSF tau and APOE. One possibility is that CSF tau combines with the APOE receptors 
in the extracellular space, indirectly modulating the intracellular transduction signaling pathways that regulate 
tau kinases activity51. In alternative, APOE4 and its C-terminal-truncated fragments could regulate directly tau 
phosphorylation and the formation of neurofibrillary tangle-like inclusions in the intracellular space of neurons52. 
At this regard, studies investigating the relationship between apoE and the microtubule-stabilizing protein tau 
showed that APOE3 binds tightly to tau, whereas APOE4 does not. These data provided the basis for hypothesiz-
ing a role for APOE in microtubule stabilization. While binding of APOE3 to tau is proposed to stabilize micro-
tubules and inhibit its hyperphosphorylation, binding deficiency of APOE4 would allow for tau self-association, 
hyperphosphorylation, and subsequent formation of paired helical filaments, the building blocks of neurofibril-
lary tangles in AD53. This experimental evidence could account for our current findings. In fact, while CSF col-
lected from APOE3 AD patients with different tau values did not influenced astrocytes survival, the samples 
collected from AD APOE4 patients affected astrocytes viability and apoptosis depending on the CSF tau levels. 
Therefore, our data show that only APOE4 may influence astrocyte survival and functionality depending on CSF 
tau levels. Given the established role of astrocytes in controlling the complex synaptic machinery at the basis of 
the mechanisms of LTP, we propose that the interaction between altered synaptic plasticity, CSF tau levels and 
APOE genotype could explain why AD patients with APOE4 allele tend to have more impaired cortical plasticity 
and eventually a more aggressive course of disease. On the other hand, the different pathophysiological mecha-
nisms linked to the presence of APOE3 allele remain to be elucidated.
A limitation of the current study is that we cannot exclude that other interactions could have taken place 
involving other molecules apart from tau in the experiments with astrocytes cultures. Therefore, further in vitro 
experiments are needed to better identify the interaction between Aβ42, t-tau and p-tau and astrocytes survival, 
to define the metabolic pathways involved in these mechanisms. Moreover additional work is required to better 
establish the pathophysiological role of CSF tau oligomers in relation to APOE polymorphism.
In conclusion, here we used a novel translational model to study the mechanisms of cortical synaptic plas-
ticity impairment occurring in AD. Our findings suggest that: i) CSF tau drives cortical plasticity impairment 
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and cognitive decline only in the presence of APOE4 genotype, while APOE3 patients seem to be characterized 
by other pathological mechanisms; ii) APOE4 patients CSF tau levels can influence astrocytes survival, inde-
pendently from Aβ levels. Thus, our data point to the existence of independent pathophysiological pathways 
mediating cognitive decline in AD patients according to the APOE polymorphism. These findings could be 
relevant to specifically address new diagnostic and therapeutic approaches targeting tau, in order to select AD 
patients according to specific clinical and biological characteristics.
Methods
Subjects. Forty-one consecutive patients recruited at the memory clinic of the University Hospital Tor 
Vergata, admitted for complaining symptoms. After the first visit to our Centre, all patients underwent for diag-
nostic purposes a complete clinical investigation in a period not superior to 60 days, including medical history, 
neurological examination, Mini-Mental State Examination (MMSE), a complete blood screening, neuropsycho-
logical assessment, magnetic resonance or CT imaging, and lumbar puncture for CSF analysis (Table 1). Patients 
fulfilled the clinical criteria of dementia as defined by the DSM-IV and probable or possible AD according to the 
criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
disease and Related Disorders Association54. Disease duration was calculated using standardized semi structured 
questionnaire55. Neurophysiological examinations were performed at the Santa Lucia Foundation within 30 days 
from CSF sampling. Patients included in this study did not receive drugs that could have modulated cerebral 
cortex excitability such as Acetylcholinesterase inhibitors (AchEI), L-Dopa or dopamine-agonists antidepres-
sants or any other neuroactive drugs (i.e. benzodiazepines, anti-epileptic drugs or neuroleptics) in the 90 days 
prior to TMS evaluation. Exclusion criteria were the following: patients with isolated cognitive deficits, patients 
with clinically manifest acute stroke in the last 6 months showing a Hachinsky scale score >4, and a radiological 
evidence of ischemic lesions, Aβ1-42 CSF values >600 pg/mL. After the neurophysiological assessment patients 
started treatment with rivastigmine patch (n = 26) or donepezil (n = 15) and were followed longitudinally with 
clinical assessments and MMSE at 6, 12 and 18 months. Twenty age, sex- and education-matched healthy subjects 
(HS) were recruited as controls. All participants or their legal guardian provided written informed consent after 
receiving an extensive description of the study. The study was performed according to the Declaration of Helsinki. 
The ethics committee of the Santa Lucia Foundation approved this protocol (Prot. CE/AG4/PROG.392-08).
CSF analysis and APOE genotype. CSF analysis was performed within routine clinical testing in patients 
with cognitive impairment. The CSF samples were collected in a polypropylene tube, directly transported to 
the local laboratory for centrifugation at 2000 × g at +4 °C for 10 minutes to eliminate cells and cellular debris, 
then stored at −80°. CSF t-tau and p-tau phosphorylated at Thr181 concentrations were determined using a 
sandwich ELISA (InnotesthTAU-Ag, Innogenetics, Gent, Belgium). Aβ1-42 levels were determined using a sand-
wich ELISA (Innotest® ß- amyloid (1–42), Innogenetics, Gent, Belgium), specifically constructed to measure 
Aβ-amyloid containing both the first and 42nd amino-acid, as previously described56. APOE genotyping was 
performed using a standard PCR. Two groups of AD patients were classified using the APOE genotype. APOE4 
group consisted of fifteen E3/E4 and five E4/E4 allele carriers AD patients while APOE3 group consisted of 
twenty-one AD patients homozygous for E3 allele (Table 1).
Transcranial magnetic stimulation. In a first series of in vivo experiments we investigated the role of 
APOE genotype on cortical plasticity by applying theta burst stimulation (TBS) protocols29 in a large sample of 
AD patients. TBS, a form of repetitive TMS has been put forward as a reliable tool to examine cortical plasticity 
in AD patients in analogy with hippocampal plasticity assessed in animal models of AD. We verified how APOE 
polymorphism eventually affected LTP-like cortical plasticity by interacting with CSF levels of total tau, p-tau181 
and Aβ42. Motor evoked potentials (MEPs) were recorded from the right first dorsal interosseous muscle using 
9 mm diameter, Ag–AgCl surface cup electrodes. A monophasic Magstim 200 device (Magstim Co, UK) was 
used to define the motor hot spot and to assess MEPs size using standard 70 mm figure-of-eight shaped coil. The 
motor hot-spot was defined as the location where TMS consistently produced the largest MEP size at 120% of 
resting motor threshold (RMT) in the target muscle57. A second coil was connected to a biphasic Super Rapid 
Magstim stimulator (Magstim Co, UK) to deliver TBS. In the intermittent-TBS (iTBS) protocol, a 2 s train of TBS 
was repeated twenty times, every 10 seconds for a total of 190 seconds (six-hundred pulses)58. The intensity of the 
test pulse was adjusted so that it evoked a MEP of about 1 mV peak-to-peak amplitude in each individual. Twenty 
MEPs were collected and averaged at baseline. Then, over the same hot-spot, twenty MEPs were recorded at 1–5, 
6–10, 11–15, 16–20 and 21–25 minutes after TBS and averaged.
Primary astrocytes culture. Lonza NHAs were purchased from Euroclone (Pero, Italy) and cultured 
according instructions. These experiments were performed at the University of Bologna. NHAs were seeded in 
75 cm2 flasks containing astrocyte basal medium (ABM™) at 37 °C in 5%CO2 humidified incubator, changing the 
growth medium the day after and every other day thereafter. The cells were sub-cultured when they were 70–80% 
confluent and containing many mitotic figures. New culture flasks were prepared by adding pre-warmed medium 
and the flasks were returned in the incubator. In a sterile field the medium was aspirated from flask and the cells 
were rinsed with 5 ml of room temperature HEPES-BSS and after a brief swirling were removed and replaced with 
2 ml of trypsin/EDTA solution and placed the flask in the 37 °C incubator for 3 to 4 minutes for trypsinization. 
After detached, the cells suspension was quickly transferred to a sterile 15 ml centrifuge tube. The cell suspension 
was then centrifuged at 160 × g to 200 × g for 5 minutes at 2 °C to 8 °C. The supernatant was aspirated and the cell 
pellet was re-suspended in 2 ml of AGM™ medium (Lonza) and the cells were seeded at density of 5,000 cells/cm2 
to a tissue culture flask or dish (pre-filled with pre-warmed medium).
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The cells were seeded into a 24 cell plates at the recommended density (10,000 cells/cm2). The day after 
medium was changed with 500 µl of fresh medium and 100 µl of CSF from AD patients with different tau levels 
was added to a final 1:6 dilution38. Using the same methods, cells were also incubated in CSF derived from healthy 
control (HC) subjects. In accordance with the institution’s ethical standards which prevent the recruitment of 
healthy people for CSF collection, the control group is composed of astrocytes treated with CSF collected from 
patients that received lumbar puncture and did not show any feature of neurological disorder.
Cell viability was assessed by Guava ViaCount Reagent (Millipore) that contains 7-amino-actinomycin D 
(7-AAD). Briefly, NHA (105 cells/sample) were diluted 1:1 with the reagent and incubated at room temperature 
in the dark for 5 min before detection with Guava EasyCyte 5 Flow Cytometer (Millipore); at least 10,000 cells/
sample were analyzed.
Apoptosis was also assayed by measuring caspase-3/7 activity using Guava Caspase 3/7 FAM kit (Millipore) 
following manufacturer’s instructions. NHA (105 cells/sample) were harvested following 24 h, 5 and 7 days treat-
ment with AD patients’ CSF, and incubated in Caspase Reagent Working Solution for 1 hour at 37 °C in a CO2 
incubator. Then cells were washed twice and labeled with Caspase 7-ADD working solution for 10 min at room 
temperature. Astrocytes were analyzed on a Guava EasyCyte 5 flow cytometer (Millipore); at least 10,000 cells/
sample were analyzed.
To confirm data on NHA apoptosis obtained with Caspase 3/7 assay, phycoerythrin-conjugated annexin V 
(annexin V-PE) and 7-AAD (Guava Nexin Reagent, Millipore) method was used to determine the percentage 
of viable, early-apoptotic and late apoptotic/necrotic cells by flow cytometry. Astrocytes (105 cells/sample) were 
harvested following 24 h, 5 and 7 days treatment with AD patients’ CSF and resuspended in 100 μl of complete 
medium; the cells were then stained with 100 μl annexin V-PE and 7-AAD for 20 min at room temperature in the 
dark, following manufacturer’s instructions, and analyzed on a Guava EasyCyte 5 flow cytometer (Millipore). 
Three populations of cells can be distinguished by this assay: viable cells (annexin V-PE and 7-AAD negative), 
early apoptotic cells (annexin V-PE positive and 7-AAD negative), and late stages apoptosis or necrotic cells 
(annexin V-PE and 7-AAD positive).
Statistical analysis. The analysis was performed using SPSS for Windows version 11.0. The assumptions and 
calculations at the bases of the sample size were 90% power to detect, using a two-sided alpha-level of 5%, a differ-
ence between APOE groups of at least 2.2 point in MMSE at 18 months. Data were presented as mean ± standard 
deviation (SD) or as mean ± standard deviation (SEM) as reported. Kruskal-Wallis analysis of variance was per-
formed for analyzing the difference among 3 or more independent groups, followed by Mann-Whitney U test 
with Bonferroni correction when significant, χ2 test was used for categorical variables. Univariate associations 
between iTBS-induced cortical plasticity (individual mean value), cognitive decline (delta score with baseline 
evaluation) and CSF biomarkers levels were investigated using Pearson’s correlation analysis or Spearman’s Rho 
analysis, as appropriate. For TMS experiments, two-way repeated measure ANOVAs were performed on MEPs 
amplitude expressed as percentage of change in comparison to baseline for iTBS protocol with TIME (1–5, 6–10, 
11–15,16–20, and 21–25 min after iTBS) as within subjects factors and GROUP (APOE3, APOE4 and HS) as 
between subjects factor. The Greenhouse-Geisser correction was used for non-spherical data. When a significant 
main effect was reached, paired t-test with Bonferroni correction was employed. A p value of <0.05 was consid-
ered to be significant.
For in vitro assays, every experimental group was composed by cells treated with CSF from four different 
patients. In viability and apoptosis measurements performed with Guava, each reading at least 10.000 cells/sam-
ple was analyzed in triplicate. The statistical analysis was performed using GraphPad Prism. A one-way ANOVA 
followed by a post-hocBonferroni multiple comparison test was used for parametric data; a Kruskal-Wallis test, 
followed by Dunn’s multiple comparisons test was used for non-parametric data. Values of p < 0.05 were consid-
ered as being significant.
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